You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the TRIPTODUR KIT (triptorelin pamoate) Drug Profile, 2024 PDF Report in the Report Store ~

TRIPTODUR KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Triptodur Kit, and what generic alternatives are available?

Triptodur Kit is a drug marketed by Azurity and is included in one NDA. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the triptorelin pamoate profile page.

DrugPatentWatch® Generic Entry Outlook for Triptodur Kit

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TRIPTODUR KIT?
  • What are the global sales for TRIPTODUR KIT?
  • What is Average Wholesale Price for TRIPTODUR KIT?
Summary for TRIPTODUR KIT
International Patents:46
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:TRIPTODUR KIT at DailyMed
Drug patent expirations by year for TRIPTODUR KIT

US Patents and Regulatory Information for TRIPTODUR KIT

TRIPTODUR KIT is protected by one US patents and one FDA Regulatory Exclusivity.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Azurity TRIPTODUR KIT triptorelin pamoate FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 208956-001 Jun 29, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Azurity TRIPTODUR KIT triptorelin pamoate FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 208956-001 Jun 29, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TRIPTODUR KIT

See the table below for patents covering TRIPTODUR KIT around the world.

Country Patent Number Title Estimated Expiration
Cyprus 1120891 ⤷  Subscribe
Japan 5419169 ⤷  Subscribe
Denmark 2164467 ⤷  Subscribe
Japan 2010529106 ⤷  Subscribe
Hungary E040391 ⤷  Subscribe
Australia 2008259411 Slow release pharmaceutical composition made of microparticles ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

TRIPTODUR KIT Market Analysis and Financial Projection Experimental

Triptodur Kit: Market Dynamics and Financial Trajectory

Introduction

Triptodur, a formulation of the drug triptorelin, is a gonadotropin-releasing hormone agonist (GnRHa) that has been gaining significant traction in the pharmaceutical market. Here, we delve into the market dynamics and financial trajectory of Triptodur Kit, highlighting its current status, growth drivers, and future outlook.

Market Size and Growth

The U.S. triptorelin market, which includes Triptodur, was valued at US$ 171.7 million in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.5% from 2022 to 2030[1].

Key Drivers of Growth

Increasing Demand for Hormonal Therapy

The demand for hormonal therapies, particularly for conditions like central precocious puberty (CPP), prostate cancer, and endometriosis, is on the rise. This increasing demand is a significant driver for the growth of the triptorelin market, including Triptodur[3][4].

Government Initiatives and Research

Government organizations and private research groups are actively involved in studying triptorelin for various applications, including breast cancer and human immunodeficiency virus (HIV). These research activities are expected to expand the market for triptorelin[1][4].

COVID-19 Pandemic Impact

The COVID-19 pandemic has accelerated the availability of Triptodur. Companies like Arbor Pharmaceuticals, LLC, have ensured continuous supply and availability of the drug, which has driven growth during the pandemic period[1][5].

Reimbursement Policies

Manufacturers are offering reimbursement policies that make Triptodur more accessible to patients. For instance, Arbor Pharmaceuticals, LLC, offers significant savings to patients undergoing treatment for CPP, which attracts more patients to choose Triptodur[1].

Market Restraints

Side Effects

Despite its efficacy, triptorelin is associated with several side effects, including tumor flare, hot flushes, decreased libido, and bone and joint pain. These side effects, as updated by the U.S. FDA in 2019, can hamper market growth[1].

High Cost of Therapy

The high cost of triptorelin therapy is another restraint. Although reimbursement policies help, the overall cost remains a significant barrier for many patients[4].

Competitive Landscape

Product Differentiation

Triptodur is the first FDA-approved twice-yearly, injectable GnRHa for the treatment of CPP. This differentiation sets it apart from other treatments and helps maintain its market position[5].

Supply Chain Stability

Arbor Pharmaceuticals and its manufacturing partner, Debiopharm, have ensured a stable supply of Triptodur, which is crucial for maintaining patient trust and compliance with treatment schedules[5].

Financial Trajectory

Current Market Value

The global triptorelin market, which includes Triptodur, was valued at US$ 910 million in 2022 and is expected to reach US$ 955.50 million in 2023. By 2033, the market is projected to grow to US$ 1556.41 million at a CAGR of 5% from 2023 to 2033[4].

Revenue Growth Indicators

  • 2022: US$ 910 million
  • 2023: US$ 955.50 million
  • 2033: US$ 1556.41 million[4].

Regional and Global Outlook

Global Expansion

The triptorelin market is not limited to the U.S.; it has a global presence. The market is expected to grow significantly in various regions, driven by increasing awareness of endocrine disorders and expanding healthcare infrastructure[4].

Regulatory Landscape

The regulatory environment varies by region, and continuous monitoring of these changes is essential to anticipate potential impacts on the market. Government policies and initiatives to raise awareness about endocrine disorders also play a crucial role in market expansion[4].

Technological Advancements

Production and Distribution

Technological advancements can lower production costs and enhance the efficacy and safety of triptorelin. These advancements also improve marketing and distribution strategies, contributing to overall market growth[4].

Key Takeaways

  • The U.S. triptorelin market, including Triptodur, is expected to grow at a CAGR of 5.5% from 2022 to 2030.
  • Increasing demand for hormonal therapies and government research initiatives are key drivers.
  • The COVID-19 pandemic has accelerated the availability of Triptodur.
  • Reimbursement policies and stable supply chains are crucial for market growth.
  • Side effects and high therapy costs are significant restraints.
  • The global triptorelin market is projected to reach US$ 1556.41 million by 2033.

FAQs

1. What is Triptodur used for? Triptodur is used for the treatment of pediatric patients 2 years and older with central precocious puberty (CPP) and is also indicated for other conditions such as prostate cancer[2][5].

2. How has the COVID-19 pandemic impacted the Triptodur market? The COVID-19 pandemic has driven the growth of the Triptodur market by ensuring continuous supply and availability of the drug, despite the challenges posed by the pandemic[1][5].

3. What are the side effects associated with Triptodur? Triptodur is associated with side effects such as tumor flare, hot flushes, decreased libido, and bone and joint pain, as updated by the U.S. FDA in 2019[1].

4. How does the reimbursement policy for Triptodur work? Arbor Pharmaceuticals, LLC, offers a reimbursement policy that allows patients to save up to US$ 10,000 per year on Triptodur treatments, making the drug more affordable for those insured by Medicaid, Medicare, or other federal or state healthcare programs[1].

5. What is the projected market size of the global triptorelin market by 2033? The global triptorelin market is projected to reach US$ 1556.41 million by 2033, growing at a CAGR of 5% from 2023 to 2033[4].

Cited Sources:

  1. Coherent Market Insights, "U.S. Triptorelin Market Size, Trends and Forecast to 2028".
  2. Ambetter Health, "Clinical Policy: Triptorelin Pamoate (Trelstar, Triptodur)".
  3. PMR Market Research, "Worldwide Triptorelin Acetate API Market Research 2024 by Type, Application, Participants, and Countries Forecast to 2030".
  4. Future Market Insights, "Triptorelin Market Size, Growth, Trends & Forecast 2033".
  5. BioSpace, "Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur (triptorelin) for Patients with Central Precocious Puberty".

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.